SyntheX

4:00 PM - 4:15 PM (EDT), Tuesday, October 22, 2019 ・ 2nd Floor
SyntheX uses synthetic biology to create the next generation of drug discovery platforms for modulating protein-protein interactions (PPIs). Using genetically engineered cells, our platform technology relies on intracellular drug selection as opposed to in vitro screening. We have developed ToRPPIDO to discover disruptors of PPIs, and ToRNeDO to discover functional protein degraders using an E3 ligase and a neosubstrate of interest. The platforms can use our DNA encoded peptide and macrocycle libraries, or small molecule screening.
Our lead program, STX100, targets an intracellular PPI within the homologous recombination (HR) DNA repair pathway. We have discovered and characterized a new cell death mechanism that exploits the differential abundance of the HR target in cancer cells relative to healthy tissue to elicit an acute calcium-dependent cell death upon binding of STX100 to its target. This program demonstrated in-vivo efficacy and a remarkable synergy with checkpoint inhibitors.
Company Type:
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2016
Main Therapeutic Focus:
Lead Product in Development:
STX100
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2